世界のフェニルプロパノールアミン（PPA）市場 – 2030年までの業界動向と予測

フェニルプロパノールアミン（PPA）市場分析と規模

PPA またはフェニルプロパノールアミンは、空腹感を抑え、充血除去剤として機能するための合成物質です。フェニルプロパノールアミン (PPA) 市場は、新興経済国の顧客の可処分所得の増加と、この薬のさまざまな組み合わせでの使用によってもたらされるいくつかの変化により、上記の予測期間中に急成長し始めるでしょう。                   

Data Bridge Market Research は、フェニルプロパノールアミン市場は 2023 年から 2030 年の予測期間中に 5.8% の CAGR で成長すると予測しています。薬物使用の普及率の高まりにより、フェニルプロパノールアミン市場の薬物タイプ セグメントでは「店頭販売」が主流となっています。市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、Data Bridge Market Research がまとめた市場レポートには、詳細な専門家分析、患者の疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

フェニルプロパノールアミン（PPA）市場の範囲とセグメンテーション

Market Definition

PPA, or phenylpropanolamine, is a synthetic substance that suppresses hunger and functions as a decongestant. It is a member of the group of medications known as sympathomimetic amines, which imitate the actions of the sympathetic nervous system. PPA was frequently found as a component in over-the-counter drugs for sinusitis, nasal congestion, and weight loss.

Phenylpropanolamine (PPA) Market Dynamics

Drivers

• Increasing awareness regarding phenylpropanolamine

For proper patient care, educating healthcare personnel about the safety issues with PPA is essential. The distribution of up-to-date knowledge regarding PPA and its alternatives is aided by clinical guidelines, continuing medical education programs, and conversations within the medical community. To encourage safe medicine usage, it is essential to inform customers about the dangers and possible adverse effects of PPA. Healthcare experts' knowledge, product labels, and consumer awareness initiatives can all assist people in making educated healthcare decisions. Thus increasing awareness regarding phenylpropanolamine is acting as a driver for market growth.

• Increasing research activities

Pharmaceutical firms or researchers may have the chance to investigate the creation of decongestants or appetite suppressants that are safer and more potent. There is still a market for these goods; innovation in this field could allay PPA's safety worries.

• Rising technological advancements

Developments can aid the development of new drugs in computational modeling, molecular biology, and high-throughput screening. These developments may eventually lead to the discovery of decongestants or appetite suppressants that are safer and more potent than PPA. Henceforth, rising technological advancements and innovations across the globe demonstrate the market's future growth.

Opportunities

• Rising usage of combination products

In medicine, phenylpropanolamine was frequently used in conjunction with other active substances. It may be possible to create medicines addressing several symptoms or health issues, for example, by combining decongestant characteristics with other therapeutic advantages. This might satisfy changing consumer preferences and needs. This creates a major opportunity for the market.

• Rising healthcare expenditure

The expense of money a country uses on its healthcare and its growth rate over time is inclined by a wide variety of economic and social factors, including the financing arrangements and structure of the organization of the health system. Healthcare expenditure has increased across developed countries and emerging economies as people's disposable income rises. Hence, colossal healthcare expenditure is a favorable factor for market growth.

• Increasing demand for personalized medicine

Personalized medicine has been made possible by developing technology like genetic testing, biomarker identification, and data analytics. This method customizes medical care to each person's specific traits and requirements. Although not directly connected to PPA, personalized medicine may influence the creation of upcoming drugs and treatment plans. These affirmative factors enhance the opportunity for market growth.

Challenges/ Restraints

• Regulatory guidelines

Governmental constraints on regulatory freedom have greatly impacted the world PPA market. Many nations have outright outlawed PPA use or imposed onerous restrictions on its sale and distribution. These regulatory efforts restrict the use of PPA-based goods by reducing their availability and market potential. Thus, regulatory guidelines for phenylpropanolamine may hamper the market's future growth.

• Safety concerns

Safety issues related to its use have been the main barrier to the market for PPA. It has been related in studies to a higher risk of stroke, particularly in women. As a result, regulatory bodies in numerous nations have taken steps to limit or forbid the sale of drugs that contain PPA. The demand for PPA has decreased, and consumers are switching to other decongestants and appetite suppressants due to safety concerns.  Thus, safety concerns for phenylpropanolamine may hamper the market growth.

• Availability of alternatives

In addition, the market expansion has been constrained by the advent of safer substitutes. Pharmacies and academics have created and marketed substitute decongestants and appetite suppressants with superior safety profiles as worries about PPA's safety have grown. There is now less demand for PPA because more patients and healthcare professionals are switching to these safer substitutes.

• The cost associated with biomarker discovery

Consumer choices and awareness significantly shape the market dynamics. The difficulty is raising customer awareness of the safety issues around PPA and encouraging safer substitutes. Effective marketing tactics and awareness-raising efforts are needed to adapt to changing customer preferences and raise public awareness. Thus, changing consumer preferences and awareness regarding phenylpropanolamine may challenge the market's growth.

This phenylpropanolamine (PPA) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the phenylpropanolamine (PPA) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Phenylpropanolamine (PPA) Market Scope

The phenylpropanolamine (PPA) market is segmented on the basis of indication, chemistry, application, drug type, population type, dosage form, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Indication

• Colds
• Hay fever
• Upper respiratory allergies
• Sinusitis
• Others

Application

• Human
• Veterinary

Drug Type

• Over the Counter
• Prescription

Population Type

• Children
• Adults

Dosage Form

• Solid dosage form
• Tablets
• Capsules
• Liquid dosage form
• Others

End User

• Hospitals
• Specialty Clinics
• Home healthcare
• Others

Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies
• Others

Phenylpropanolamine (PPA) Market Regional Analysis/Insights

The phenylpropanolamine (PPA) market is analysed and market size insights and trends are provided by indication, chemistry, application, drug type, population type, dosage form, end user and distribution channel as referenced above.

The countries covered in the phenylpropanolamine (PPA) market report are U.S., Canada, Mexico, Brazil, Argentina, Peru, rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, rest of Middle East and Africa.

Asia-Pacific governs the market industry due to the drug's availability in OTC and prescription and rising disposable income. At the same time, Europe is anticipated to expand at the leading germination pace from 2023 to 2030 due to the presence of an isomeric form of this drug in the European market.

フェニルプロパノールアミン (PPA) 市場レポートの国別セクションでは、市場の現在および将来の動向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。消費量、原材料費、下流および上流のバリュー チェーン分析などのデータ ポイントは、各国の市場シナリオを予測するために使用される主要な指標の一部です。また、国別データの予測分析を提供する際には、グローバル ブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、国内関税と貿易ルートの影響も考慮されます。

ヘルスケアインフラの成長 導入ベースと新技術の浸透

フェニルプロパノールアミン (PPA) 市場は、患者分析、予後、治療法に関する詳細な市場分析も提供します。有病率、発症率、死亡率、遵守率は、レポートで利用可能なデータ変数の一部です。疫学の市場成長への直接的または間接的な影響分析は、成長期の市場を予測するためのより堅牢なコホート多変量統計モデルを作成するために分析されます。

競争環境とフェニルプロパノールアミン（PPA）市場シェア分析

フェニルプロパノールアミン (PPA) 市場の競争状況は、競合他社ごとに詳細を提供します。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性が含まれます。提供されている上記のデータ ポイントは、フェニルプロパノールアミン (PPA) 市場に関連する会社の焦点にのみ関連しています。

フェニルプロパノールアミン (PPA) 市場で活動している主要企業は次のとおり です。

• RIEMSER Pharma GmbH (ドイツ)
• アボット（米国）
• ヘリコン（カナダ）
• EIPICO（エジプト）
• Schazoo Pharmaceuticals Pvt. Ltd (パキスタン)
• グラクソ・スミスクライン（英国）
• ロマース SAICF (アルゼンチン)
• タージ・ファーマシューティカルズ（インド）
• シプラ社（インド）
• メドライン インダストリーズ (米国)
• サノフィ（フランス）
• Tempo Scan Pacific Tbk Carinopharm (インドネシア)
• IBLヘルスケア（インド）
• PT. グラシア・ファルミンド（インドネシア） 

SKU-60010